IP Library › Granted Patent US 12678490
Granted Patent B2
US 12678490 · App. 17/551,904 · Granted Jul 14, 2026

Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol

Inventors: John Michael Beals (Indianapolis, IN); Eric Dwayne Hawkins (Carmel, IN); Anthony Shane Ransdell (Plainfield, IN); Shantanu Virendra Sule (Arlington, MA); Monica Rixman Swinney (Stoneham, MA)
Assignee: ELI LILLY AND COMPANY
A61K38/28A61K31/167A61K31/196A61K31/5415A61K31/573A61K31/625A61K31/727A61K33/30A61K47/10A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678490
App. No.
17/551,904
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.

Claims (5)

1 . A method of treating diabetes comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising:

(a) rapid acting insulin or ultra-rapid acting insulin;

(b) m-cresol; and

(c) meloxicam,

wherein the insulin concentration is from about 100 U/mL to about 500 U/mL, the concentration of m-cresol is from about 2.5 mg/mL to about 3.8 mg/mL, and the concentration of meloxicam is from about 0.015 mg/ml to about 5.0 mg/mL.